Today Nycomed Amersham Imaging announced its acquisition of the Bruker Tomojet power injector system from Swiss firm Bruker. Tomojet is a pump injector for the administration of contrast media for diagnostic investigations, and is available in versions suitable for both MR and CT applications, according to Nycomed Amersham of Buckinghamshire, U.K.
Typical applications for Tomojet include: contrast angiography, tumor diagnostics, organ perfusion, and incremental body imaging, according to Nycomed Amersham. Tomojet is currently being marketed in Europe and other international markets, and will continue to be manufactured by Bruker in Zurich, Switzerland.
By AuntMinnie.com staff writersJanuary 24, 2001
Related Reading
E-Z-EM inks European deal with Nycomed-Amersham, December 18, 2000
Copyright © 2001 AuntMinnie.com
![Axial images from unenhanced calcium score cardiac CT (left) and curved planar reformation images from CT angiography (right) show that higher long-term exposure to air pollution is associated with greater coronary artery calcium and more obstructive coronary artery disease (CAD). Top row: Images in a 68-year-old male patient with higher 10-year mean ambient air pollution exposure (7.9 μg/m3 for particulate matter measuring ≤2.5 μm in diameter [PM2.5] and 17.4 parts per billion [ppb] for NO2) with extensive CAD (coronary artery calcium score [CACS] >1,000 and obstructive CAD [≥70% diameter stenosis]). Bottom row: Images in a 57-year-old female patient with lower 10-year mean ambient air pollution exposure (6.3 μg/m3 for PM2.5 and 4.6 ppb for NO2) with no CAD (CACS = 0 and no obstructive stenosis).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/06/hanneman.r6SMLzkezo.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
